Design Therapeutics (DSGN) Interest Expenses (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Interest Expenses data on file, last reported at $3.4 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 32.07% year-over-year to $3.4 million; the trailing twelve-month figure through Mar 2026 stood at $3.4 million (down 65.24% YoY), and the FY2025 full-year result was $53.7 billion, up 173.41% from the prior year.
• Interest Expenses rose to $3.4 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $10.5 billion in Q4 2022 to a low of $1.3 million in Q3 2023.
• A 5-year average of $687.6 million and a median of $2.5 million in 2025 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses surged 215.36% in 2023 and sank 99.76% in 2024, its largest moves.
• Tracing DSGN's Interest Expenses over 5 years: stood at $10.5 billion in 2022, then sank by 89.41% to $1.1 billion in 2023, then slumped by 99.76% to $2.6 million in 2024, then fell by 17.1% to $2.2 million in 2025, then jumped by 53.52% to $3.4 million in 2026.
• Business Quant data shows DSGN's Interest Expenses at $3.4 million in Q1 2026, $2.2 million in Q4 2025, and $2.3 million in Q3 2025.